China Tobacco Hong Kong 2023FY: 42% YoY Increase Driven by Cigarette Export and Operations in Brazil

Business by 2FIRSTS.ai
Mar.12.2024
China Tobacco Hong Kong 2023FY: 42% YoY Increase Driven by Cigarette Export and Operations in Brazil
China Tobacco Hong Kong (06055.HK) announced a 42% revenue increase in 2023, driven by tobacco import and export growth.

Recently, China Tobacco Hong Kong (06055.HK) announced its financial results for the year ending in 2023. The company reported a revenue of 11.836 billion Hong Kong dollars, representing a 42% year-on-year increase. The gross profit was 1.088 billion Hong Kong dollars, up 35% from the previous year. The net profit attributable to shareholders reached 599 million Hong Kong dollars, showing a 60% year-on-year increase.

China Tobacco Hong Kong 2023FY: 42% YoY Increase Driven by Cigarette Export and Operations in Brazil
Image source: China Tobacco Hong Kong

 

China Tobacco Hong Kong announced that the overall financial performance of the group has experienced growth, mainly driven by the increase in import and export businesses of tobacco products, as well as growth in operations in Brazil.

 

In this period, the export quantity of cigarettes was 2,803,867 thousand units, an increase of 2,420,560 thousand units year-on-year, with a growth rate of 631%. Operating income was 1,208.7 million Hong Kong dollars, an increase of 1,084.9 million Hong Kong dollars year-on-year, with a growth rate of 876%. Gross profit was 164.0 million Hong Kong dollars, an increase of 151.1 million Hong Kong dollars year-on-year, with a growth rate of 1,167%.

 

The export quantity of new tobacco products reached 677,310 thousand units, an increase of 174,920 thousand units compared to the previous year, marking a growth of 35%. The operating revenue was 130.0 million Hong Kong dollars, an increase of 19.8 million Hong Kong dollars compared to the previous year, showing a growth of 18%. The gross profit was 5.7 million Hong Kong dollars, an increase of 2.5 million Hong Kong dollars compared to the previous year, representing a growth of 80%.

 

China Tobacco Brazil's partially owned subsidiary, CBT, exported a total of 32,396 tons of tobacco products to regions outside of China, representing a year-on-year increase of 3,149 tons or 11%. The company's revenue reached 766.3 million Hong Kong dollars, with a year-on-year increase of 223.1 million Hong Kong dollars or 41%. The gross profit was 141.0 million Hong Kong dollars, up by 27.5 million Hong Kong dollars or 24% compared to the previous year.

 

China Tobacco Hong Kong stated that in 2024, it will continue to promote product research and development upgrades, enhance brand cultivation, expand into emerging markets, and increase the sales volume of new tobacco products.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Juul Labs displayed its JUUL2 e-cigarette system alongside existing products, age-verification messaging and mobile coupons, 2Firsts observed. The JUUL2 device and Virginia Tobacco and Polar Menthol pods received FDA marketing authorization in August 2026. Booth materials highlighted longer battery life, greater e-liquid capacity and connected-device features. A TruAge sign and a mobile coupon presentation also featured at the booth, with weekly offers available to age-verified adult nicotine consumers at participating retailers.
EXPO
Oct.09
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26